Agarwal Sanjeev Kumar
Cardiology, Rashid Hospital, Dubai, UAE.
Cardiovasc Revasc Med. 2014 Jul-Aug;15(5):308-10. doi: 10.1016/j.carrev.2014.04.005. Epub 2014 Apr 30.
Dual antiplatelet therapy including aspirin and a P2Y12 ADP receptor antagonist is given after percutaneous coronary intervention to avoid catastrophic complication of stent thrombosis. Dual antiplatelet therapy is associated with increased bleeding risk and may not be tolerated by many patients. This article presents the patients, which had to be given single antiplatelet therapy after percutaneous coronary intervention and discusses the possible factors responsible for the success of single antiplatelet therapy strategy in these patients, in the current era of newer antiplatelet agents and coronary stents.
经皮冠状动脉介入治疗后给予包括阿司匹林和P2Y12 ADP受体拮抗剂在内的双重抗血小板治疗，以避免支架血栓形成这一灾难性并发症。双重抗血小板治疗会增加出血风险，且许多患者可能无法耐受。本文介绍了经皮冠状动脉介入治疗后必须接受单一抗血小板治疗的患者，并讨论了在当前使用新型抗血小板药物和冠状动脉支架的时代，这些患者单一抗血小板治疗策略成功的可能因素。
